Ira Mellman

Ira Mellman

Auto-generated profile, based on publicly available information

Ira Mellman

Genentech

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2011 in Nature
Verified
Journal Article
Closed access
PDF file
IMIra Mellman
Ira Mellman
GCGeorge Coukos
George Coukos
GDGlenn Dranoff
Glenn Dranoff

31 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
EHEnfu Hui
Enfu Hui
JCJeanne Cheung
Jeanne Cheung
JZJing Zhu
Jing Zhu
XSXiaolei Su
Xiaolei Su
MTMarcus J. Taylor
Marcus J. Taylor
RVRonald D. Vale
Ronald D. Vale
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.

10 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
LRLuis A. Rojas
Luis A. Rojas
ZSZachary Sethna
Zachary Sethna
SKSoares Kevin
Soares Kevin
COCristina Olcese
Cristina Olcese
NPNan Pang
Nan Pang
VBVinod P. Balachandran
Vinod P. Balachandran
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients1, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3. Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8+ T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.

10 October 2023 in Immunity
Verified
Journal Article
Open access
IMIra Mellman
Ira Mellman
DCDaniel S. Chen
Daniel S. Chen
TPThomas Powles
Thomas Powles
STShannon J. Turley
Shannon J. Turley
The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. Here, we update the cancer-immunity cycle based on the remarkable progress of the past decade. Understanding the mechanism of checkpoint inhibition has evolved, as has our view of dendritic cells in sustaining anti-tumor immunity. We additionally account for the role of the tumor microenvironment in facilitating, not just suppressing, the anti-cancer response, and discuss the importance of considering a tumor's immunological phenotype, the "immunotype". While these new insights add some complexity to the cycle, they also provide new targets for research and therapeutic intervention.

1 March 2016 in Immunity
Verified
Journal Article
Closed access
PEPeter J.R. Ebert
Peter J.R. Ebert
JCJeanne Cheung
Jeanne Cheung
YYYagai Yang
Yagai Yang
EMErin McNamara
Erin McNamara
RHRebecca Hong
Rebecca Hong
IMIra Mellman
Ira Mellman

24 March 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
STSiri Tahtinen
Siri Tahtinen
ATAnn-Jay Tong
Ann-Jay Tong
PHPatricia Himmels
Patricia Himmels
JOJaehak Oh
Jaehak Oh
APAndres Paler-Martinez
Andres Paler-Martinez
IMIra Mellman
Ira Mellman